RADIOLABELED COMPOUNDS

The present invention relates to radiolabeled compounds of formula I 2. The radiolabeled compound of claim 1 , wherein{'sup': '1', 'sub': '1-7', 'Ris Calkyl,'}{'sup': '2', 'sub': '1-7', 'Ris Cfluoroalkyl,'}{'sup': '3', 'Ris methyl,'}{'sup': 4', '2', '18', '3', '3', '11, 'Ris hydrogen, wherein either Ris labeled with F or H, or Ris labeled with C.'}3. The radiolabeled compound of claim 1 , wherein{'sup': 1', '2, 'Rand Rtogether with the nitrogen atom to which they are attached, form a heterocycloalkyl, preferably morpholinyl,'}{'sup': '3', 'Ris methyl,'}{'sup': 4', '4', '18, 'sub': '1-7', 'Ris Cfluoroalkyoxy, wherein Ris labeled with F.'}4. The radiolabeled compound of claim 1 , wherein{'sup': 1', '2, 'Rand Rtogether with the nitrogen atom to which they are attached, form a heterocycloalkyl, preferably morpholinyl,'}{'sup': '3', 'Ris methyl,'}{'sup': 4', '4', '3', '11, 'sub': '1-7', 'Ris Calkyoxy, wherein Ris either labeled with H or C.'}69.-. (canceled)10. A method for positron emission tomography (PET) imaging of PDE10A in tissue of a subject claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) administering an effective amount of a compound of to the subject,'}b) allowing the compound to penetrate into the tissue of the subject; andc) collecting a PET image of the CNS or brain tissue of the subject.11. A method for the detection of PDE10A functionality in a tissue of a subject claim 1 , the method comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) administering an effective amount of a compound of to the subject,'}b) allowing the compound to penetrate into the tissue of the subject; andc) collecting a PET image of the CNS or brain tissue of the subject.12. (canceled)13. A pharmaceutical composition comprising a compound as claimed in and a pharmaceutically acceptable excipient.14. (canceled) The present invention relates to radiolabeled compounds of formula IwhereinRand Rare independently selected from Calkyl, ...

Trans-cyclooctene labeled antisense oligonucleotides, radio labeled tetrazine and methods

Featured are trans-cyclooctene and tetrazine compounds. Also provided are methods for evaluating the biodistribution and/or concentration of a biomolecule in a subject.

Radiolabeled compounds

The present invention relates to radiolabeled compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein.

Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality

The present invention relates to radiolabelled compounds of formula (I), which are useful for the labelling and diagnostic imaging of 5-HT6 receptor functionality, and the treatment of CNS related disorders.

Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität

Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality

The present invention relates to radiolabelled compounds of formula (I), which are useful for the labelling and diagnostic imaging of 5-HT<SUB>6</SUB> receptor functionality, and the treatment of CNS related disorders.

Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität

4-haloethenylphenyl tropane:serotonin transporter imaging agents

A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes and 4-haloethenylphenyl tropane families are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.

4-haloethenylphenyl tropane:serotonin transporter imaging agents

A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes and 4-haloethenylphenyl tropane families are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.

4-haloethenylphenyl tropane:serotonin transporter imaging agents

A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes and 4-haloethenylphenyl tropane families are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.